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Abstract
Introduction: Wiskott–Aldrich syndrome (WAS) is characterized by microthrombocytopenia, eczema, recurrent infections, and an
increased incidence of autoimmunity. Commonly, classic WAS is presented with severe clinical symptoms.
Case Presentation: We report a new phenotype of classic Wiskott–Aldrich syndrome with mild symptoms in two cousins who were
7 years old. They had not severe infections or hemorrhage, in spite of having genetic mutation in WAS gene. The symptoms and
infections of the patients responded to treatment with IVIG and antibiotics.
Conclusions: This report is presenting a novel clinical phenotype of classic WAS with milder symptoms.
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1. Introduction
Wiskott–Aldrich syndrome (WAS) is a rare, X-linked
primary immune deficiency (PID), characterized by
impaired cellular and humoral immunity, micro-
thrombocytopenia, and eczema (1) with an incidence
of approximately 1:100,000 live births. It is associated with
an increased risk of autoimmunity and malignancy (2).
WAS occurs due to a hemizygous mutation in the gene
of WAS protein (WASP) in location Xp11.22-23 (3). WASP
plays an important role in signaling pathways for reorga-
nization of actin cytoskeleton which is widely expressed
in the cytoplasm of hematopoietic cells (4). Defects in the
function of WASP lead to the impairment of cellular and
humoral immunity as well as platelet (PLT) formation (5).
Therefore, as the result of WASP gene mutation, clinical
phenotypes with differing symptom severity occur. These
phenotypes include classic WAS with severe symptoms and
poor prognosis, and two other milder phenotypes called X-
Linked thrombocytopenia (XLT) and X-Linked neutropenia
(XLN) (6). Hematopoietic stem cell transplantation (HSCT)
at present is the only curative method (3). In this report,
a novel phenotype of classic WAS with mild clinical symp-
toms and without need to HSCT is presented.
2. Case Presentation
Patient 1: A 7-year-old boy was referred to allergy clinic
at Bushehr University of Medical Sciences, Iran, with com-
plaints of wheezing, dry skin and infection. He was the first
child born to consanguineous parents. At age 2, he was
hospitalized for the first time with high grade fever due
to severe cold, followed by respiratory distress and ecchy-
mosis. PLT count was 30000/mL. A bone marrow biopsy
was performed to evaluate underlying etiology of throm-
bocytopenia. Idiopathic thrombocytopenic purpura (ITP)
and asthma were diagnosed and he was treated with pred-
nisolone and oral beclomethasone spray. During the age
3 to 6, he was suffering from asthma attacks and admit-
ted to ICU for several times. Also, he developed gener-
alized eczema when he was 6 years old. Two of his un-
cles were reported to have died in childhood after experi-
encing similar symptoms. Physical examination revealed
generalized eczema and normal growth. Laboratory tests
showed microcytic thrombocytopenia with PLT count of
30000/mL and WBC 6000/ml with 50% neutrophils, 38%
lymphocytes and 5% eosinophils. The results of the assess-
ment of humoral and cellular immune systems by using
ELISA and flow cytometry methods are shown in Table 1. Ul-
timately, the diagnosis of WAS was suggested and sequenc-
ing for WAS gene performed. Hemizygous missense mu-
tation, NG_007877.1: g. 1974G > A, c. 397G > A, p. E133K,
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a known disease-causing mutation variant for the classi-
cal WAS was reported (Figure 1). Treatment with IVIG (400
mg/kg, monthly) started and for infection prophylaxis Cot-
rimoxazole applied. The clinical symptoms subsided and
thrombocytopenia was corrected.
Patient 2: A 7-year-old boy, cousin to patient 1 referred
to the clinic with symptoms of joint pain and swelling.
At the age of 2.5, he had urticaria and was hospitalized
for arthritis. Interestingly, his arthritis started in fall,
and aggravated following the treatment with antibiotics.
PLT count was decreased to below 50000/ml and WBC
5400/ml with 52% neutrophils, 36% lymphocytes and 4%
eosinophils. When 5 years old, he was referred to rheuma-
tologist for severe arthritis symptoms and was treated with
prednisolone. After treatment, PLT increased to 175000/ml.
Finally, his cellular and humoral immune systems were as-
sessed and the results are shown in Table 1. The result of
gene assessment of the patient indicated hemizygous mis-
sense mutation of NG_007877.1: g. 1974G > A, c. 397G > A in
WAS gene (Figure 1). Therefore, the patient was treated with
IVIG (400 mg/kg, monthly) and received cotrimoxazole for
prophylaxis.
In both patients, no hepatosplenomegaly, no lym-
phadenopathy but a moderate eczema was seen in physi-
cal exam. After one month, no response to HBV vaccine and
normal isohemagglutinin antibody was seen. Gene assess-
ment of the patients was done in experimental laboratory
of immunology, Catholic University of Leuven, Belgium.
Table 1. Immunological Findings of Two Patients with Classic WAS
Value Patient 1 Patient 2
WBC (n) 6000 5400
CD3 (%) 23 17.4
CD4 (%) 2.9 5.8
CD8 (%) 2.5 9.5
CD19 (%) 5.8 24.3
CD16CD56 (%) 7.8 15.2
IgG (mg/dl) 1167 1090
IgA (mg/dl) 333.5 230
IgM (mg/dl) 71 55
IgE (IU/ml) 230.3 178
3. Discussion
In this report, we describe a different phenotype of
two cousins with classic WAS showing mild clinical symp-
toms. Classic WAS presents in early childhood with a hem-
orrhagic diathesis due to microthrombocytopenia, and
recurrent infections with extensive eczema. The clinical
symptoms are usually severe in those classic WAS patients
with chronic eczema and frequent lymphadenopathy and
hepatosplenomegaly (1). Moreover, patients with the clas-
sic WAS phenotype should be usually treated with allo-
geneic HSCT (7). It is vital to treat classic WAS patients with
severe symptoms and infections as soon as diagnosis is es-
tablished (8). A study performed in Japan on 57 WAS pa-
tients treated with HSCT showed that 5 year-old patients
suffering from classic WAS, at the time of transplantation
had increased susceptibility to infection and hemorrhage
diathesis had shown already poor prognosis. Therefore,
timely diagnosis and starting treatment of WAS seems to
be very important (9). Interestingly, in our study all the
symptoms and infections vanished after treatment with
monthly IVIG and prophylactic antibiotics, and treatment
with HSCT was not needed.
In addition, XLT, the milder form of WAS, resulting
from the mutation in WAS gene, causes decrease in protein
expression of WASP. It is characterized mainly by throm-
bocytopenia which is associated with milder eczema and
immunodeficiency (10). To our knowledge, more than 300
mutations of the WAS gene among various ethnic groups
have been reported to affect protein expression of WASP.
Genetic investigation in our cases revealed the occurrence
of classic WAS phenotype missense mutations.
In conclusion, our results suggest that a new pheno-
type of classic WAS may be present, which manifest milder
clinical symptoms.
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